Senesco Technologies Reports On Results Of Preclinical Multiple Myeloma Studies
Senesco Technologies, Inc. (”Senesco” or the “Company”) (Amex: SNT) announced the results of preclinical animal studies focused on multiple myeloma that were conducted concurrently at Mayo Clinic and the University of Waterloo. The goal of these studies, which utilized two different dosing regimens, was to further test the ability of Senesco’s Factor 5A technology to induce apoptosis in tumors.
More: continued here
Filed under: Blood on February 7th, 2008